bio IMeD
BioIMeD develops AI-driven medical devices that automate liquid biopsy procedures using microfiltration, microfluidic chips, and precision sensors to enhance diagnostic accuracy. Their technology addresses the lengthy analysis times and labor-intensive processes associated with traditional biopsy methods, achieving over 90% diagnostic precision while significantly increasing throughput.
- Artificial Intelligence
- Biotechnology
- Healthcare Technology
- Medical Devices
Funding
Founders
Product
Problem
Traditional liquid biopsy analysis is a lengthy and labor-intensive process, often requiring significant manual intervention and specialized expertise. Existing methods can suffer from limitations in cell recovery and extended analysis times, hindering timely diagnostic insights.
Solution
BioIMeD is developing an AI-driven medical device to automate liquid biopsy procedures, integrating microfiltration, microfluidic chips, precision sensors, and an optical system. The device aims to streamline the isolation and identification of target cells from liquid biopsies, reducing analysis time and minimizing manual handling. By automating the process, BioIMeD's technology seeks to enhance diagnostic accuracy, increase throughput, and provide clinicians with reliable results more efficiently. The integrated AI algorithms analyze the data, enabling rapid and accurate identification of relevant cells, and reducing the time required for analysis.
Target Audience
The primary target audience includes clinical laboratories, hospitals, and research institutions involved in cancer diagnostics and personalized medicine.
Features
- Automated liquid biopsy processing using microfiltration and microfluidic technology
- Integrated optical system and precision sensors for cell detection and analysis
- AI-powered algorithms for automated cell identification and data analysis
- Streamlined workflow to reduce analysis time and manual labor
- High cell recovery rate
- Intended to integrate directly into clinical practice